Evaluation of prognostic factors for myeloperoxidase anti-neutrophil cytoplasmic antibody- (MPO-ANCA) associated glomerulonephritis.
OBJECTIVE
To identify prognostic factors for myeloperoxidase anti-neutrophil cytoplasmic antibody- (MPO-ANCA) associated glomerulonephritis.


METHODS
We analyzed the relations between the clinical and histological features of MPO-ANCA-associated glomerulonephritis and clinical outcome in 14 patients with the disease. The patients were divided into two groups: group 1 consisted of 5 patients with progressive deterioration of renal function leading to end-stage renal disease or chronic dialysis, group 2 consisted of 9 patients in whom the initial deterioration of renal function had improved by the time of the final examination.


RESULTS
Creatinine clearance at the time of biopsy was significantly lower in group 1 than in group 2, and urinary protein was higher. The mean interval between onset of symptoms and biopsy in both groups was almost the same. Recovery of renal function was correlated with the percentage of global sclerosis, but patients who had severe crescent formation did not always have a poor response to steroid therapy. There was no statistical difference between the two groups in treatment regimens. Four patients required hemodialysis at the time of biopsy (3 in group 1 and 1 in group 2). Plasmapheresis was performed in 5 patients (1 in group 1 and 4 in group 2).


CONCLUSIONS
Degree of proteinuria and renal dysfunction are indicators of a poor prognosis in MPO-ANCA-associated glomerulonephritis. Global sclerosis is a histological feature that is an indicator of a poor prognosis, whereas cellular crescent formation is a predictor of a good response to steroid therapy.
Okano
K
K
Department of Medicine, Kidney Center, Tokyo Women's Medical University, Japan. okanokz@ss.iij4u.or.jp
Yumura
W
W
Nitta
K
K
Honda
K
K
Uchida
K
K
Nihei
H
H
D000328:Adult; D000368:Aged; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D001323:Autoantibodies / Q000097:blood*; D003404:Creatinine / Q000378:metabolism; D018450:Disease Progression; D005260:Female; D005921:Glomerulonephritis / Q000276:immunology / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009195:Peroxidase / Q000276:immunology*; D010951:Plasma Exchange; D011379:Prognosis; D011507:Proteinuria; D006435:Renal Dialysis
D019268:Antibodies, Antineutrophil Cytoplasmic; D001323:Autoantibodies; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003404:Creatinine; D009195:Peroxidase